Skip to main content

Table 3 Multivariable logistic regression analysis of possible variables (P<0.05 in univariate logistic regression analysis) predicting pCR

From: A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer

  P OR 95 % CI
Tumor size
 T1   1  
 T2 0.186 0.576 0.255-1.304
 T3 0.544 0.737 0.275-1.975
 T4 0.015 0.281 0.101-0.779
Hormone receptor status
 Negative   1  
 Positive <0.001 0.224 0.125-0.400
Regimens
 Cyclophosphamide, epirubicin and 5-fluorouracil   1  
 Cyclophosphamide, epirubicin and 5-fluorouracil followed by paclitaxel or docetaxel and epirubicin 0.208 4.673 0.423-51.590
 Navelbine and epirubicin 0.078 6.999 0.804-60.897
 Paclitaxel and carboplatin or paclitaxel and cisplatin 0.003 27.696 3.131-245.030
Cycles
 3-4   1  
 1-2 0.500 0.579 0.118-2.834
 5-6 0.217 2.338 0.606-9.017
  1. Abbreviations: pCR pathological complete response, OR odds ratio, CI confidence interval